

Date: February 14, 2025

BSE Limited Listing Department- Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001 Scrip Code: 544292	National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400051 Symbol: ONESOURCE
---	--

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Change in Senior Management Personnel

The Board of Directors (“Board”) of OneSource Specialty Pharma Limited (“Company”) via Circulation on February 14, 2025 have considered and approved the appointment of Mr. Bernhard Thurnbauer as the Chief Quality Officer (CQO) of the Company effective from March 01, 2025.

The details required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Annexure:

Sl. No.	Particulars	Details
1.	Reason for change viz. appointment/ re-appointment/ resignation/ removal/ death or otherwise	Appointment of Mr. Bernhard Thurnbauer as the Chief Quality Officer (CQO) of the Company in line with the Internal Governance Structure of the Company.
2.	Date of appointment/ re- appointment / cessation (as applicable) & term of appointment / re-appointment	Date of appointment by the Board: February 14, 2025 Effective date of appointment: March 01, 2025 Term of Appointment: Not Applicable
3.	Brief profile (in case of appointment)	Enclosed
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Brief Profile of Bernhard Thurnbauer

Bernhard Thurnbauer is a highly accomplished pharmaceutical executive with over 30 years of leadership experience in quality assurance, compliance, and technical operations. He has held senior positions in global biotech and pharmaceutical companies, including Moderna, Roche, Acino, and B. Braun. His expertise spans sterile injectables, biologics, CDMO operations, and regulatory compliance across USFDA, EMA, and other global health authorities.

As Chief Quality Officer at OneSource, Bernhard would lead the company’s global quality strategy, ensuring the highest regulatory and operational excellence. His vision focuses on developing high performing teams, transforming quality processes through artificial intelligence and aligning quality with business growth.

Before joining OneSource, Bernhard was the Global Head of Audit Program Management at Moderna, overseeing a US-based team responsible for ensuring compliance with stringent global regulatory requirements. He played a pivotal role in shaping audit strategies, implementing risk-based approaches and driving efficiency improvements.

Earlier in his career, Bernhard founded a manufacturing IT and compliance consultancy in Bangkok, leveraging his extensive industry experience to help pharmaceutical companies optimize operations. He is an active member of professional organizations such as ISPE and PDA.

Outside of work, Bernhard enjoys traveling, exploring different cultures, and spending time by the sea.